Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes

We want to investigate the effects of pioglitazone on cardiovascular events in Japanese patients with type 2 diabetes.

Completed

Looking for future studies?

Key information

Conditions

Type 2 Diabetes Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetic Nephropathies Diabetic Nephropathy Dyslipidemia Dyslipidemias Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glucose Metabolism Disorders Hypertension Kidney Diseases Lipid Metabolism Disorders Male Urogenital Diseases Metabolic Diseases Nutritional and Metabolic Diseases Urogenital Diseases Urologic Diseases Vascular Diseases

Age range

20 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Dokkyo Medical University, Koshigaya Hospital

Koshigaya, Saitama, 343-8555, Japan

About this study

Primary composite endpoints:

Cardiovascular death Non-fatal myocardial infarction and angina Non-fatal stroke Renal failure (hemodialysis/doubling of serum creatinine)

Secondary endpoints:

urinary albumin excretion diabetic retinopathy hyperlipidemia hypertension gout

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

type 2 diabetes HbA1c: more than 7% and less than 9%

Exclusion criteria

insulin treatment

Treatment and study plan

pioglitazone

Drug

Sponsors and collaborators

Lead sponsor

Dokkyo Medical University

Other

Registry information

Important dates

Study start: 2004
Study completion: 2008
First posted: Jan 8, 2007
Registry last updated: Jan 8, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed